LURATI, ALFREDOMARIA
LURATI, ALFREDOMARIA
Universita' degli Studi di MILANO
Efficacy of a second TNFAlpha blocker when the first one failed in patients with juvenile idiopathic arthritis (JIA) treated with Infliximab, Etanercept and Adalimubab
2008 A. Salmaso, V. Gerloni, A. Lurati, I. Pontikaki, B. Teruzzi, M. Gattinara, F. Fantini
Skeletal mineralization in a prepubertal female population affected by juvenile idiopathic arthritis
2008 A. Lurati, R. Cimaz, M. Gattinara, V. Gerloni, B. Teruzzi, A. Salmaso, F. Fantini
Long-term evaluation of infliximab in the treatment of persistently active juvenile idiopathic arthritis refractory to conventional therapy
2007 G. De Marco, V. Gerloni, I. Pontikaki, A. Lurati, B. Teruzzi, A. Salmaso, E. Valcamonica, M. Gattinara, F. Fantini
Side Effects of Anti-Tnfα Therapy in Jia, in an Open Monocentric Prospective Study of 151 Patients
2005 I. Pontikaki, V. Gerloni, A. Lurati, M. Gattinara, A. Salmaso, E. Valcamonica, G. De Marco, B.L. Teruzzi, F. Fantini
Anti-Cyclic Citrullinated Peptide Antibodies in Juvenile Idiopathic Arthritis (jia). A Monocentric Cross-Sectional Study
2005 V. Gerloni, A. Lurati, B. Teruzzi, C. Crapanzano, M. Gattinara, F. Fantini
Long-Term Evaluation (Efficacy and Safety) of Infliximab in the Treatment of Persistently Active Juvenile Idiopathic Arthritis (JIA), Refractory to Standard Treatments
2005 V. Gerloni, I. Pontikaki, G. De Marco, M. Gattinara, E. Valcamonica, A. Lurati, A. Salmaso, B. Teruzzi, F. Fantini
Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis : results of an open-label prospective study
2005 V. Gerloni, I. Pontikaki, M. Gattinara, F. Desiati, E. Lupi, A. Lurati, A. Salmaso, F. Fantini